secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2021-08-11T23:59:59+00:00
Accession:  0001558370-21-011209
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma Q2 net loss $9.2M vs $3.7M; cash $167.3M; STRIDE study first patient dosed
--------------------------------------------------------------------------------

- Net loss of $9.2M ($0.43/share) for Q2 2021, compared to net loss of $3.7M ($1.82/share) in Q2 2020.
- Cash, cash equivalents and short-term investments of $167.3M as of June 30, 2021.
- First patient dosed in Phase 2b STRIDE trial of REN001 in primary mitochondrial myopathies (PMM); McArdle disease study enrollment completed.
- R&D expenses increased to $6.3M from $2.8M; G&A expenses rose to $2.9M from $0.9M.
- Anticipated milestones: McArdle results Q1 2022, LC-FAOD results H1 2022, FORWARD study results H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000155837021011209/0001558370-21-011209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000155837021011209/rphm-20210811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-011209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer